AFFINERGY, LLC
Durham, NC · Medtech · Private
Serological diagnostic test for bioactive hepcidin-25 using proprietary peptide-based sandwich assay
- Grants
- $26M
- 50 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 7
- 1 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Phage-based assay to measure daptomycin concentration in biological fluids | $256,978 | |
| Federal grant | Department of Health and Human Services · Phase I · Beta-2 Microglobulin Depletion Columns for Amyloidosis Prevention and Treatment | $293,816 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel technologies to remove obscuring blood from fine needle aspiration biopsies | $698,109 | |
| Federal grant | Department of Health and Human Services · Phase II · Peptide-coated skin substitutes for the treatment of burn injuries and wounds | $678,615 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel technologies to remove obscuring blood from fine needle aspiration biopsies | $702,576 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel technologies for improved slide quality of pancreatic fine-needle aspirates | $301,009 | |
| Federal grant | Department of Health and Human Services · Phase II · Phage-based assay to measure daptomycin concentration in biological fluids | $668,916 | |
| Federal grant | Department of Health and Human Services · Phase II · Peptide-coated skin substitutes for the treatment of burn injuries and wounds | $734,274 | |
| Federal grant | Department of Health and Human Services · Phase I · Peptide-based slides for improving the diagnostic quality of sputum specimens | $299,999 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel technologies for the detection of podocytes from preeclamptic patients | $299,999 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Peptide based tool for the rapid isolation of quiescent monocytes from peripheral blood | $308,839 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Peptide-based tool for the rapid isolation of quiescent monocytes from peripheral blood | $308,839 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel technologies to remove obscuring blood from fine needle aspiration biopsies | $696,963 | |
| Federal grant | Department of Health and Human Services · Phase II · Stem cell-binding peptides for rapid fixation of total hip replacements | $1,496,190 | |
| Federal grant | Department of Health and Human Services · Phase I · Point-of-care device to identify patients at risk for preeclampsia | $200,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Phage-based assay to measure daptomycin concentration in biological fluids | $671,292 | |
| Federal grant | Department of Health and Human Services · Phase I · Point-of-care device to identify patients at risk for preeclampsia | $52,200 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel technologies for detection of podocytes from preeclamptic patients | $707,804 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel PhageLock assay to measure hepcidin for clinical monitoring | $333,003 | |
| Federal grant | Department of Health and Human Services · Phase I · A point-of-care assay to monitor tobramycin in cystic fibrosis patients | $299,617 | |
| Federal grant | Department of Health and Human Services · Phase I · Autoantibody profiling to develop a novel diagnostic array for systemic sclerosis | $299,244 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel assay to monitor Tacrolimus levels at the point of care | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Stem cell-binding peptides for rapid fixation of total hip replacements | $746,272 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel technologies for detection of podocytes from preeclamptic patients | $638,707 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel technologies to remove obscuring blood from fine needle aspiration biopsies | $203,640 | |
| Federal grant | Department of Health and Human Services · Phase I · A novel clinical assay for detection of APOL1 renal risk alleles | $320,013 | |
| Federal grant | Department of Health and Human Services · Phase II · Point-of-care device to identify patients at risk for preeclampsia | $752,918 | |
| Federal grant | Department of Health and Human Services · Phase II · Point-of-care device to identify patients at risk for preeclampsia | $85,290 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a multiplex peptide array to identify patients with an autoantibody signature for chronic pain | $320,058 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients | $283,225 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a novel clinical assay for measuring everolimus levels | $744,006 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Novel assay to monitor Tacrolimus levels at the point of care | $759,336 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Point-of-care device to identify patients at risk for preeclampsia | $736,241 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel technologies for detection of podocytes from preeclamptic patients | $653,488 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a multiplex point-of-care assay to identify patients with Venous Thromboembolism | $297,440 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a peptide-based diagnostic for amyotrophic lateral sclerosis | $299,778 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a novel clinical assay for measuring everolimus levels | $717,613 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients | $590,249 | |
| Federal grant | Department of Health and Human Services · Phase I · Immunoprofiling to develop a novel diagnostic array for cardiac sarcoidosis | $299,802 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel assay to monitor Tacrolimus levels at the point of care | $734,099 | |
| Federal grant | Department of Health and Human Services · Phase II · Point-of-care device to identify patients at risk for preeclampsia | $702,122 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel clinical assay to rapidly monitor posaconazole levels in plasma | $294,541 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients | $679,410 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a novel clinical assay for measuring everolimus levels | $648,895 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel assay to monitor Tacrolimus levels at the point of care | $735,018 | |
| Federal grant | Department of Health and Human Services · Phase II · A Rapid Point of Care Test for APOL1 Renal Risk Alleles | $685,035 | |
| Federal grant | Department of Health and Human Services · Phase II · A Rapid Point of Care Test for APOL1 Renal Risk Alleles | $741,371 | |
| Federal grant | Department of Health and Human Services · Phase II · Rapid assay to monitor vancomycin levels at the point of care in hemodialysis patients | $682,788 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel peptide assay for hepcidin clinical monitoring | $613,787 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel peptide assay for hepcidin clinical monitoring | $590,935 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1802 | MABDX, INC. | — | — |
| 1803 | HEARTVISTA, INC. | — | — |
| 1804 | TF HEALTH CORPORATION | — | — |
| 1805 | AFFINERGY, LLC | — | — |
| 1806 | CORAMI BIOTECH INC. | — | $230K |
| 1807 | CLEAVED DIAGNOSTIC CORPORATION | — | — |
| 1808 | HALCYON BIOMEDICAL, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Rapid Assay For APOL1 G0 Proteinapplication
- Cell Binding Peptides For Diagnosis And Detectiongranted
- Bmp Binding Peptidesapplication
- Rapid Assay For APOL1 G0 Proteinapplication
- Rapid Assay For APOL1 G0 Proteinapplication
- Cell Binding Peptides For Diagnosis And Detectionapplication
- Implantable Bone Graft Materialsapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.